A message from i2i Marketing Group, LLC 
Early Stage Matters More Than the Headline By the time a resource story becomes mainstream, positioning is usually gone. The earlier phase - when exploration is active, data is forming, and attention is limited - is where long-term narratives begin. This North American group is still operating in that phase...quietly advancing a portfolio of strategic materials tied to energy and defense demand. Work programs are underway. New data is coming in. And awareness is building. Why EARLY-stage context matters here: - Active exploration means new information ahead
- Portfolio exposure allows multiple value paths
- Macro trends support long-term relevance
- Attention remains limited - for now
This isn't about chasing momentum. It's about understanding setup. See what’s developing before the story becomes obvious >
Today's Exclusive Article Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims UndercutWritten by Leo Miller. Originally Published: 2/6/2026. 
Key Takeaways - Eli Lilly shares gained mightily after the company released its latest earnings report, with 2026 guidance coming in well past expectations.
- However, HIMS stoked fears around LLY's oral GLP-1 potential the next day, wiping out much of the stock's gain.
- After Lilly's earnings, updated price targets imply significant upside ahead for the stock.
In its latest earnings report, Eli Lilly and Company (NYSE: LLY) again demonstrated why it has become one of the world's most valuable healthcare stocks. Year-to-date, Lilly's market capitalization exceeds $900 billion—more than $300 billion larger than the next biggest name in the sector, Johnson & Johnson (NYSE: JNJ). Shares jumped more than 10% on Feb. 4 after the earnings release, but were whipsawed the next day, falling nearly 8% following an announcement from Hims & Hers Health (NYSE: HIMS). Despite the volatility, with strong growth expected in 2026 and a potential blockbuster drug on the horizon, Eli Lilly remains difficult to bet against. Lilly Provides Stunning 2026 Guidance, Catapulting Shares While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> Lilly's Q4 2025 results were impressive. The company reported sales rising 43% to $19.3 billion, handily beating expectations of $17.9 billion (implying 33% growth). Adjusted earnings per share rose 42% to $7.54, slightly above estimates of $7.48 (41% growth expected). At midpoint, Lilly expects full-year 2026 revenue of $81.5 billion and adjusted EPS of $34.25 — implying growth of 25% and 41%, respectively. That comfortably surpassed analysts' forecasts, which called for 19% revenue growth and 36% adjusted EPS growth. Meanwhile, Lilly's top competitor Novo Nordisk A/S (NYSE: NVO) projected a sales decline of 5% to 13% in 2026, highlighting the divergence between the two companies. Lilly's share of the U.S. incretin market, the category covering GLP-1 and related drugs, continued to expand. At the end of 2025, its market share stood at over 60%, versus Novo's 39% — a notable shift from roughly equal shares one year earlier. This trend is supported by clinical evidence. A 2025 study found that Lilly's injectable tirzepatide produced nearly 50% more weight loss than Novo's injectable semaglutide, which helps explain stronger prescribing for Lilly's drug. HIMS Rains on LLY’s Parade, Introducing Low-Cost Oral Copycat Oral medications are the next battleground for Lilly and Novo. Novo's oral semaglutide has already received approval from the U.S. Food and Drug Administration. Pending approval, Lilly plans to launch its oral candidate, orforglipron, in the U.S. in Q2 2026 and in most international markets in 2027. Many view orforglipron as Lilly's next potential blockbuster because it can reach patients with needle aversion and help maintain weight loss after stopping injectables. On Feb. 5, Hims & Hers announced plans to sell compounded versions of oral semaglutide, offering the drug at $49 for the first month and $99 thereafter. That undercuts Novo's monthly pricing by roughly $100 and is materially below the $149 to $399 monthly range Lilly has cited for orforglipron, depending on dosage. The announcement sent Lilly's shares down about 7.8% on Feb. 5. Investors worry Hims' lower pricing could dent demand for orforglipron and that compounded providers might attempt to replicate Lilly's oral candidate. While uncertainty remains about the long-term impact, there are reasons to think Lilly can withstand the challenge. UBS Securities analyst Michael Yee estimates there have been roughly 1 million prescriptions for compounded GLP-1s, compared with about 100 million prescriptions across Novo and Lilly's branded GLP-1 franchises. That suggests compounded GLP-1s represent only a small slice of the overall market. Hims could be a nuisance, but its ability to meaningfully hinder orforglipron's growth appears limited. Updated Targets Eye 25% Upside in LLY Shares With orforglipron's potential launch approaching and strong demand for Lilly's injectable drugs, the outlook for Eli Lilly shares remains constructive. The MarketBeat consensus price target for LLY is near $1,200, implying about 18% upside. Analyst targets updated the day after Lilly's earnings averaged $1,273, suggesting roughly 25% potential upside from current levels.
| 
0 Response to "By the Time It's a Headline, the Setup Is Gone"
Post a Comment